Rocket Pharmaceuticals (RCKTW) News Today

Rocket Pharmaceuticals, Inc. (RCKTW) shares fell today after news of a patient death prompted the U.S. Food and Drug Administration to pause and place a clinical hold on the company’s mid‐stage gene therapy trial for Danon disease, compounding pressure from a recent analyst downgrade.

• Retail investors reportedly turned bullish on the stock after the initial sell‐off, suggesting potential support at lower levels.
• Short interest remains minimal, with a days‐to‐cover ratio of 0.0 days, pointing to limited short‐squeeze dynamics.
• Rocket was highlighted among “trending tickers,” boosting the company’s market visibility.
• The firm issued a Phase 2 clinical update for RP-A501 in Danon disease, underlining continued commitment to its gene therapy pipeline.
• A participant’s death in the RP-A501 trial triggered an FDA pause and clinical hold, raising safety and regulatory concerns.
• Needham downgraded Rocket Pharmaceuticals, adding to selling pressure on the stock.
• The share price plunged in pre‐market trading following the trial hold, reflecting investor anxiety over the program’s future.